why choose us

First received: September 12, 2023

Clinical Trial: Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Non-small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: Assessing the Immunomodulatory Effects of Pharmacologic Ascorbate With Durvalumab (MEDI 4736) in Non-Small Cell Lung Cancer: A Window of Opportunity Trial

Brief Summary: This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab

Read more